<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654196</url>
  </required_header>
  <id_info>
    <org_study_id>HL_HL301_301</org_study_id>
    <nct_id>NCT03654196</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab. in Acute Bronchitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase III Clinical
      Trial to Evaluate the Efficacy and Safety of HL301 versus Umkamin tab. in acute bronchitis
      patients

      Endpoint: BSS, The improvement and improvement rate of the tester for the treatment response,
      The satisfaction of the subject
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Actual">September 21, 2018</completion_date>
  <primary_completion_date type="Actual">September 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchitis Severity Total Score(BSS) Change</measure>
    <time_frame>Visit 1 (-3 day), Visit 2 (0 day), Visit 3 (7 day)</time_frame>
    <description>The BSS comprises the following five symptoms typical for Acute Bronchitis: cough, sputum, rales on auscultation, chest pain on coughing, and dyspnoea. These symptoms are each assessed according to a 5-point Likert scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The improvement and improvement rate of the tester for the treatment</measure>
    <time_frame>Visit 3 (7 day)</time_frame>
    <description>Improvement and improvement rate are assessed by tester according to a 5 factors: Deterioration, No change, Slight to moderate improvement, Major improvement, Complete recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The satisfaction of the subject (Questionnaire)</measure>
    <time_frame>Visit 3 (7 day)</time_frame>
    <description>Satisfaction of the subject (Questionnaire) are assessed by subject according to a 5 factors: Very dissatisfied, Dissatisfied, Neutral, Satisfied, Very satisfied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Acute Bronchitis</condition>
  <arm_group>
    <arm_group_label>HL301(Experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Umkamin(Active Comparator)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL301(Experimental)</intervention_name>
    <description>Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]</description>
    <arm_group_label>HL301(Experimental)</arm_group_label>
    <other_name>HL301 and Placebo of Umkamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Umkamin(Active Comparator)</intervention_name>
    <description>Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]</description>
    <arm_group_label>Umkamin(Active Comparator)</arm_group_label>
    <other_name>Placebo of HL301 and Umkamin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Both gender, 19 years ≤ age ≤ 80 years

          2. (Bronchitis Severity Score)* ≥ 5point at Visit 2 (Randomized Visit)

          3. Acute bronchitis within 48hr based on Visit 2 (Randomized Visit)

          4. Those who can comply with the requirements of clinical trials

          5. Written consent voluntarily to participate in this clinical trial

        Exclusion Criteria:

          1. Patients with respiratory and systemic infections requiring systemic antibiotic
             therapy

          2. Patients with bleeding tendency

          3. Patients who investigators determines to severe respiratory disease that would
             interfere with study assessment

          4. Patients who were treated with oral systemic adrenocortical hormone or
             immunosuppressive drug within 4 weeks prior to Visit 2

          5. Patients who were treated with oral antihistamines, ACE suppressive. or
             systemic/inhalative glucocorticosteroid within 2 weeks prior to Visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>February 10, 2019</last_update_submitted>
  <last_update_submitted_qc>February 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Bronchitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

